Odds ratios (95 % CI) for ER-defined breast cancer across plasma enterolactone concentration (low/high) in women from the MDC cohort, 1991 to 2004
| . | ENL concentration . | . | P for heterogeneity . | |
|---|---|---|---|---|
| . | Low . | High . | . | |
| ENL concentration (nmol/L), median (range) | 8.4 (0.3-16.1) | 26.3 (16.1-334.4) | ||
| Cases/controls | 204/366 | 162/367 | ||
| OR (95% CI) | 1.00 | 0.75 (0.58-0.98) | ||
| ERα (−) tumors | ||||
| Cases/controls | 27/366 | 25/367 | ||
| OR (95% CI) | 1.00 | 0.86 (0.48-1.54) | ||
| ERα (+) tumors | ||||
| Cases/controls | 175/366 | 134/367 | ||
| OR (95% CI) | 1.00 | 0.73 (0.55-0.97) | 0.62* | |
| ERβ (−) tumors | ||||
| Cases/controls | 113/366 | 72/367 | ||
| OR (95% CI) | 1.00 | 0.60 (0.43-0.85) | ||
| ERβ (+) tumors | ||||
| Cases/controls | 91/366 | 90/367 | ||
| OR (95% CI) | 1.00 | 0.94 (0.67-1.33) | 0.04† | |
| ERα (+)/ERβ (−) tumors | ||||
| Cases/controls | 93/366 | 59/367 | ||
| OR (95% CI) | 1.00 | 0.59 (0.41-0.86) | ||
| ERα (+)/ERβ (+) tumors | ||||
| Cases/controls | 82/366 | 75/367 | ||
| OR (95 % CI) | 1.00 | 0.90 (0.63-1.28) | 0.08‡ | |
| . | ENL concentration . | . | P for heterogeneity . | |
|---|---|---|---|---|
| . | Low . | High . | . | |
| ENL concentration (nmol/L), median (range) | 8.4 (0.3-16.1) | 26.3 (16.1-334.4) | ||
| Cases/controls | 204/366 | 162/367 | ||
| OR (95% CI) | 1.00 | 0.75 (0.58-0.98) | ||
| ERα (−) tumors | ||||
| Cases/controls | 27/366 | 25/367 | ||
| OR (95% CI) | 1.00 | 0.86 (0.48-1.54) | ||
| ERα (+) tumors | ||||
| Cases/controls | 175/366 | 134/367 | ||
| OR (95% CI) | 1.00 | 0.73 (0.55-0.97) | 0.62* | |
| ERβ (−) tumors | ||||
| Cases/controls | 113/366 | 72/367 | ||
| OR (95% CI) | 1.00 | 0.60 (0.43-0.85) | ||
| ERβ (+) tumors | ||||
| Cases/controls | 91/366 | 90/367 | ||
| OR (95% CI) | 1.00 | 0.94 (0.67-1.33) | 0.04† | |
| ERα (+)/ERβ (−) tumors | ||||
| Cases/controls | 93/366 | 59/367 | ||
| OR (95% CI) | 1.00 | 0.59 (0.41-0.86) | ||
| ERα (+)/ERβ (+) tumors | ||||
| Cases/controls | 82/366 | 75/367 | ||
| OR (95 % CI) | 1.00 | 0.90 (0.63-1.28) | 0.08‡ | |
NOTE: Adjusted for age, date of blood collection, weight, height, smoking status, educational status, and current use of menopausal hormone therapy.
Test of heterogeneity between ERα (−) and ERα (+) tumors.
Test of heterogeneity between ERβ (−) and ERβ (+) tumors.
Test of heterogeneity between ERα (+)/ERβ (−) and ERα (+)/ERβ (+) tumors.